Allakos Inc., a clinical stage biopharmaceutical company located in San Carlos, California, is making strides in the development of therapeutics that target immunomodulatory receptors on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody, lirentelimab (AK002), is currently in Phase III trials for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis, as well as in Phase II/III trials for eosinophilic esophagitis and a Phase II clinical trial for atopic dermatitis and chronic spontaneous urticaria. Allakos Inc. is not stopping there and is also working on developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis, while simultaneously moving forward with AK006 to treat allergic and inflammatory diseases. Furthermore, the company is conducting preclinical studies for AK007, a therapeutic solution that polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. Established in 2012, Allakos Inc. is bringing cutting-edge advancements in biopharmaceuticals to the forefront with its innovative approaches to treating various diseases.
Allakos Inc.'s ticker is ALLK
The company's shares trade on the NASDAQ stock exchange
They are based in Redwood City, California
There are 51-200 employees working at Allakos Inc.
It is https://www.allakos.com/
Allakos Inc. is in the Healthcare sector
Allakos Inc. is in the Biotechnology industry
The following five companies are Allakos Inc.'s industry peers: